BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) whose disease had progressed despite sorafenib therapy in the phase 3 CELESTIAL trial reported to the 2018 ESMO World Congress on Gastrointesinal Cancer. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.207 “This is a new oral drug [that’s] very easy for […]